DOD Biotech Public Co., Ltd.

As of June 30, 2026, DOD Biotech Public Co., Ltd. carries a market capitalization of 581.03M, placing it among publicly traded companies globally. Its enterprise value stands at 534.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, DOD Biotech Public Co., Ltd. has 450.41M shares outstanding.

As of June 30, 2026, DOD Biotech Public Co., Ltd. trades at a trailing price-to-earnings ratio of 314.55. The price-to-sales ratio is 1.11, and the price-to-book ratio stands at 0.63.

As of June 30, 2026, DOD Biotech Public Co., Ltd. trades at an EV/EBITDA multiple of 12.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 534.82M versus a market cap of 581.03M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, DOD Biotech Public Co., Ltd. maintains a current ratio of 2.93, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.40, indicating elevated leverage, while an interest coverage ratio of 12.08 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, DOD Biotech Public Co., Ltd. posted a return on equity (ROE) of 0.20, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.17, measuring how efficiently the asset base is converted into earnings. Inventory turnover of 3.38 indicates how many times DOD Biotech Public Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, DOD Biotech Public Co., Ltd. recorded an income tax benefit of -9.66M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -4.86M and 1.87M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, DOD Biotech Public Co., Ltd.'s stock has declined approximately 58.03% over the past 52 weeks. The 50-day moving average sits at 0.89, while the 200-day moving average is 1.40.

Over the twelve months ended June 30, 2026, DOD Biotech Public Co., Ltd. generated 529.06M in revenue and converted that into 1.87M in net income, yielding earnings per share of 0.01. EBITDA reached 41.58M, while operating income came in at -550,198.00.

As of June 30, 2026, DOD Biotech Public Co., Ltd. holds 110.35M in cash and equivalents against 67.65M in total debt, resulting in a net debt position of 8.18M. Total book value stands at 917.90M, with working capital of 255.03M providing operational flexibility.

DOD Biotech Public Co., Ltd. produced -22.95M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -72.27M in capital expenditures, free cash flow totaled -95.22M - equivalent to -0.21 per share.

Over the twelve months ended June 30, 2026, DOD Biotech Public Co., Ltd. posted a gross margin of 30.81, reflecting its pricing power and cost economics. The operating margin of -0.10 and net profit margin of 0.35 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.28, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to DOD Biotech Public Co., Ltd. shareholders.

DOD Biotech Public Co., Ltd.'s most recent stock split took place on May 12, 2023.

As of June 30, 2026, DOD Biotech Public Co., Ltd. has an Altman Z-Score of 2.49, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.